Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intralesional Rituximab for Conjunctival Lymphoma (IRIS)
NCT01514344Phase 2Completed
- Start
- Dec 2011
- Primary completion
- Oct 2014
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of rituximab in conjunctival lymphoma. Started Dec 2011; status: completed.
02
Drugs
rituximab
03
Conditions
conjunctival lymphoma
Beyond the preview
Go deeper on NCT01514344.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01514344.